DUBLIN – By late 2019, early stage Finnish biotech firm Herantis Pharma plc aims to have a readout from its lead development program, which involves the intracerebral delivery of a first-in-class neurotrophic growth factor to Parkinson's disease patients, and to have completed recruitment onto a phase I/II trial of a novel gene therapy in patients with lymphedema arising from breast cancer treatment.